A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | MicrobiomeTrials← Back to trialsNCT05415072
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-07-04Est. Completion: 2027-10-01
Enrollment target: 66 participants Locations- Massachusetts General Hospital, Boston, Massachusetts, United States
- Columbia University Medical Center, New York, New York, United States
- Memorial Sloane Ketterin Cancer Ctr, New York, New York, United States
- Novartis Investigative Site, Westmead, New South Wales, Australia
- Novartis Investigative Site, Melbourne, Victoria, Australia
- Novartis Investigative Site, Paris, France
- Novartis Investigative Site, Essen, Germany
- Novartis Investigative Site, Heidelberg, Germany
- Novartis Investigative Site, Leiden, South Holland, Netherlands
- Novartis Investigative Site, Madrid, Spain
- Novartis Investigative Site, Zurich, Switzerland
Other microbiome trials you might be interested in
Metastatic Uveal Melanoma
Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to …
Paris, FranceCompleted Apr 28, 2025
Uveal Melanoma
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Boston, United StatesCompleted May 5, 2020